Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AEON with free AI briefings, catalyst countdowns, and dilution alerts.

AEON · AEON Biopharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.4M Cash on Hand
3.3mo Cash Runway
Follow AEON by email Get an email when AEON reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AEON, unsubscribe in one click. Privacy

📣 What AEON Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ABP-450 Migraine Phase 2 · NCT05016661 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AEON holds $3.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.2M/quarter from operations, an estimated runway of 3.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AEON files for a raise →

👥 Who Owns AEON

Insiders 48.3% Other 5%+ holders 14.3% Institutions 22.9% Public and other holders 14.5%
HolderTypeShares% of sharesAs of
Daewoong Co., Ltd
10% owner · +8.00M options
Insider 23,242,546 27.63% 2026-10-30
Daewoong Co.,Ltd. ("DWC") 5%+ holder (13D) 12,009,737 14.28% 2026-01-21
Ikarian Capital, LLC Institution (13G, 5%+) 7,362,438 8.75% 2026-09-30
Stonepine Capital Management, LLC Institution (13G, 5%+) 6,892,682 8.19% 2026-07-15
Timothy P Lynch
10% owner
Insider 5,350,000 6.36% 2026-08-19
Nantahala Capital Management, LLC Institution (13G, 5%+) 5,048,027 6.00% 2026-09-30
Robert E. Bancroft
PRESIDENT & CEO, Director · +59,034 options
Insider 3,177,103 3.78% 2026-02-17
Chad Oh
CHIEF MEDICAL OFFICER · +1.83M options
Insider 2,183,436 2.60% 2026-02-17
Alexander Blair Wilson
CLO, CSO, and Corp Secretary · +1.80M options
Insider 2,183,005 2.60% 2026-02-17
Jennifer Sy
PRINCIPAL ACCOUNTING OFFICER · +973,988 options
Insider 1,501,176 1.78% 2026-02-17
Marc Forth
Director · +1.63M options
Insider 973,231 1.16% 2026-06-17
John Bencich
CHIEF FINANCIAL OFFICER
Insider 754,717 0.90% 2026-04-02

Share count 84,121,648 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AEON picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AEON and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.